Streetbeat News

Stock Prices

SEIC

SEI Investments Company has expanded its stock repurchase program by $400 million, increasing the total authorization to approximately $429 million. This move indicates the company's confidence in its financial health and commitment to returning value to shareholders.

Portfolio Pulse from Benzinga Newsdesk

October 22, 2024 | 8:36 pm

CSGP

CoStar shares declined following the release of disappointing Q3 revenue results.

Portfolio Pulse from Benzinga Newsdesk

October 22, 2024 | 8:36 pm

PKG

Packaging Corp shares rose following the release of their Q3 financial results, which exceeded expectations.

Portfolio Pulse from Benzinga Newsdesk

October 22, 2024 | 8:35 pm

TXN

Texas Instruments reported Q3 earnings that beat estimates, but provided weak Q4 guidance. The company reported earnings of $1.47 per share and revenue of $4.151 billion, both above expectations. However, Q4 earnings and revenue guidance fell short of analyst estimates.

Portfolio Pulse from Erica Kollmann

October 22, 2024 | 8:35 pm

BROS

SBUX

Dutch Bros shares are experiencing a decline in response to Starbucks' Q4 financial results and the suspension of its 2025 guidance.

Portfolio Pulse from Benzinga Newsdesk

October 22, 2024 | 8:35 pm

TSLA

Tesla (NASDAQ:TSLA) has significantly outperformed the market over the past decade, with an annualized return of 29.7%. A $100 investment in Tesla 10 years ago would now be worth $1,474.96, highlighting the power of compounded returns.

Portfolio Pulse from Benzinga Insights

October 22, 2024 | 8:34 pm

MANH

Manhattan Associates shares are trading lower following the release of their Q3 financial results.

Portfolio Pulse from Benzinga Newsdesk

October 22, 2024 | 8:34 pm

PFSI

PennyMac Financial Services reported Q3 2024 adjusted earnings per share of $3.49, surpassing the analyst consensus estimate of $2.90 by 20.34%.

Portfolio Pulse from Benzinga Newsdesk

October 22, 2024 | 8:33 pm

NTB

Bank of N.T Butterfield (NYSE:NTB) reported Q3 2024 earnings per share of $1.16, surpassing the analyst estimate of $1.14. The company's sales were $142.7 million, slightly above the expected $142.472 million, marking a 0.71% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

October 22, 2024 | 8:32 pm

ANRO

Alto Neuroscience announced that its Phase 2b study of ALTO-100 for Major Depressive Disorder did not meet its primary endpoint, as measured by the Montgomery-Åsberg Depression Rating Scale, compared to placebo.

Portfolio Pulse from Benzinga Newsdesk

October 22, 2024 | 8:32 pm